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Abstract
BACKGROUND
In recent years, increasing evidence of second neoplasms associated with
gastrointestinal stromal tumors (GIST) has been found. Numerous case reports,
mostly retrospective studies and a few reviews, have been published. To our
knowledge, however, no systematic review or meta-analysis of the existing data
has been performed so far.
AIM
To prepare a compilation, as complete as possible, of all reported second tumor
entities that have been described in association with GIST and to systematically
analyze the published studies with regard to frequency, localization, and types of
GIST-associated neoplasms.
METHODS
The MEDLINE and EBSCO databases were searched for a combination of the
keywords GIST/secondary, synchronous, coincident/tumor, neoplasm, and
relevant publications were selected by two independent authors.
RESULTS
Initially, 3042 publications were found. After deletion of duplicates, 1631
remained, and 130 papers were selected; 22 of these were original studies with a
minimum of 20 patients, and 108 were case reports. In the 22 selected studies,
comprising a total number of 12050 patients, an overall rate of GIST-associated
neoplasias of 20% could be calculated. Most second neoplasias were found in the
gastrointestinal tract (32%) and in the male and female urogenital tract (30%). The
specific risk scores of GISTs associated with other tumors were significantly
lower than those without associated neoplasias.
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CONCLUSION
In this first systematic review, we could confirm previously reported findings of a
more than coincidental association between GIST and other neoplasias. The
question whether there is an underlying causal association will need further
investigation. Our data suggest that even GIST with a very low risk of disease
progression should prompt screening for second neoplasia and subsequent
frequent controls or extended staging.
Key words: Gastrointestinal stromal tumor; Associated; Secondary; Neoplasia; Tumor
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Core tip: Gastrointestinal stromal tumors (GIST) associated neoplasms have been
previously reported to occur with a more than coincidental frequency. Numerous case
reports, mostly retrospective studies and a few reviews have been published on this
topic. In this, to our knowledge, first systematic review we analyzed 108 case reports and
22 retrospective and prospective studies with a total of 12050 patients. An overall rate of
GIST-associated neoplasias of 20% could be calculated. Most second neoplasias were
found in the gastrointestinal tract (32%) and in the male and female urogenital tract
(30%).
Citation: Waidhauser J, Bornemann A, Trepel M, Märkl B. Frequency, localization, and types
of gastrointestinal stromal tumor-associated neoplasia. World J Gastroenterol 2019; 25(30):
4261-4277
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INTRODUCTION
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of
the digestive tract. Yearly incidence rates vary from 4.3 to 22 per million in different
geographic regions, which may at least in part be caused by changing and improving
diagnostic criteria and a lack of established GIST registries. In most studies, however,
the yearly incidence is indicated as 10 to 15 per million[1], fulfilling the criterion of a
rare disease. Median age at diagnosis is reported to be between 60 and 69 years in
most studies[1,2]. GIST are considered to develop from interstitial cells of Cajal (ICC),
which play an important role in autonomous gastrointestinal movement[3]. The most
common localization of GIST is the stomach, followed by other gastrointestinal tract
localizations[2,4].
Several driver mutations have been identified as playing an essential role in the
development of GIST. The most frequent mutation can be found in the tyrosine kinase
receptor c-kit (c-KIT), which accounts for 70%-80% of GIST[5-7] and is nowadays the
most important target of medical tumor therapy in GIST patients. Other relevant
mutations  can  be  observed in  the  platelet-derived growth factor  receptor  alpha
(PDGFR-α) in 5%-10%[5-7] and, in rare cases, in other genes such as neurofibromin 1
(NF1), succinate dehydrogenase (SDH), or BRAF[6,8].
GIST can occur in the setting of genetic syndromes such as neurofibromatosis 1[9],
Carney triad[10], or familial GIST[11] and, in these cases, frequently come along with
other  benign  or  malignant  neoplasias.  In  recent  years,  though,  there  has  been
increasing evidence of second neoplasia in patients with sporadic GIST[12-15]. Several
retrospective studies and case series have been published on this topic, complemented
by many case reports  and a few reviews,  but  so far  to our knowledge,  no meta-
analysis or systematic reviews have been conducted. The aim of this first systematic
review is to prepare a compilation, as complete as possible, of all reported second
tumor entities that have been described in association with GIST and to systematically
analyze the published studies with regard to frequency, localization, and types of
GIST-associated neoplasms.
MATERIALS AND METHODS
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Literature research
We performed a literature search in the MEDLINE and EBSCO databases, using the
keywords GIST/secondary, synchronous, coincident/tumor, neoplasm. All results
were transferred to the citation manager Endnote® and duplicates were deleted. The
remaining  results  were  screened  by  two  authors  with  regard  to  suitable  topic,
language, and publication standard. Discrepancies were resolved after discussion
with a senior third author. Case reports and case series/studies in English or German
were included. Only data that was fully published was eligible. Syndromic settings as
familial GIST or neurofibromatosis were excluded as well as cases involving children.
Studies had to include at least 20 patients, and studies that investigated only one
specific kind of second neoplasm were excluded. Second neoplasms were considered
regardless of the time frame between their occurrence and the occurrence of GIST.
Malignant  as  well  as  benign  second  neoplasms  were  selected.  In  addition,  the
bibliographies of all selected papers that were published between 2016 and 2019 were
screened for suitable references, as were the six published reviews on this topic.
Statistical analysis
For statistical calculations, we used SigmaPlot 13.0 (Systat, Erkrath, Germany) and
Microsoft Excel (Microsoft Office 16). The chi-squared test was performed for testing
the  relationship  between  two  categorical  variables.  A  aP-value  of  <  0.05  was
considered significant.
PROSPERO registration
Before starting the literature research, a registration of this systematic review in the
international Prospective Register of Systematic Reviews (PROSPERO, registration
number CRD42019122784) was performed.
RESULTS
The literature search revealed a total of 3042 publications before February 2019. After
deletion  of  duplicates,  1631  papers  remained.  Screening  by  the  two  authors
(Waidhauser J and Bornemann A) resulted in 126 eligible papers. In addition, one
study on 188 GIST patients that was performed at our institute by Mayr et al[15] and
had not been published by the time of the literature search was included. Of the 130
selected publications, 108 were case reports and 22 were case series or retrospective
and prospective studies (Figure 1).
All additional neoplasms that were reported in the case reports are listed in Table 1.
The most frequent types were gastric and colorectal adenocarcinomas.
Among the 22 retrospective and prospective studies, a total of 12050 patients were
included. Basic information on these studies is summarized in Table 2. The number of
patients in which an additional tumor to the GIST diagnosis was found was 2426
(20.1%). The median age at the diagnosis of GIST was 63 years in the total study
population and 68 years in those patients with an additional tumor. The male-to-
female ratio was 1.1:1 in the total population and 1.4:1 in the GIST with secondary
neoplasia group. The chi-squared test revealed a significant difference for the sex
distribution of P < 0.001 with a predominance of male gender in cases with associated
neoplasia (Table 3).
Of 2248 patients, for whom the respective data were available, 253 benign (11%)
and 1995 (89%) malignant neoplasias were reported, with the restriction that in some
studies, only patients with malignant second neoplasias were included. Chronological
considerations  revealed  that  50%  (366  of  732)  of  second  neoplasias  occurred
synchronously to GIST, 26% (187 of 732) occurred before GIST, and 24% (179 of 732)
were diagnosed after GIST. Focusing on synchronous second neoplasias, a rate of 6%
(366 of 5131) was detected among all GIST patients. Of these synchronous second
neoplasias 77% (177 of 230) occurred in the GI-Tract and 7% (16 of 230) in the male
and  female  urogenital  tract.  The  distribution  of  different  histological  subtypes
(spindle vs  epithelioid vs  mixed) revealed no differences between the GIST-only
patients and the patients with another neoplasm (spindle: 78% vs 80%; epithelioid: 8%
vs 6%; mixed: 14% vs 14%) (Table 4).
Figure 2 gives an overview of the different localizations of the GIST-associated
neoplasias. The most common manifestation was seen in the gastrointestinal tract
(32%),  followed by urogenital  and female  genital  tract  (30%);  10% of  additional
tumors  were  found in  the  breast  and 6% each in  the  lung and in  the  blood and
lymphatic system.
Regarding the risk scores for disease progression or recurrence of GIST, there was a
significantly (P < 0.001) higher proportion of very low- and low-risk GIST in patients
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Figure 1
Figure 1  Flow of analysis based on the retrieved literature. GIST: Gastrointestinal stromal tumors.
with an additional tumor (65%) compared to the GIST-only group (35%), whereas in
this latter group, the portion of intermediate and high-risk patients was higher (69%
vs 31%). For calculation, we used the risk scores as they were applied in the different
studies, which were most frequently those according to Fletcher et al[4] or Miettinen et
al[16] (Table 5).
The  mutational  status  of  driver  genes  in  patients  with  GIST  and  associated
neoplasias was reported in only four of the 22 studies, with a total of 167 patients.
These patients with GIST and second tumors showed mutations in exon 11 of the KIT
gene in 69%, non-exon-11 mutations of the KIT gene in 6%, mutations in the PDGFR-α
gene in 13%, and a “wildtype” status in 13%.
Data on follow-up was very heterogeneously reported or not available in most of
the included studies, which is why even a descriptive analysis was not feasible.
DISCUSSION
In our systematic review, we detected a rate of 20.1% of second neoplasias in GIST
patients,  with  the  most  frequent  localization  of  associated  tumors  in  the
gastrointestinal  tract  and  in  the  urogenital  and  female  genital  tract.  Previously
described rates of GIST-associated neoplasias varied between 11% and 50%[13,17]. The
general probability of being diagnosed with cancer twice in a lifetime is estimated
between 2% and 17% (syndromic settings or familial predisposition included)[18] or in
other words with a chance of 1:9[12,19]. Compared to this number the rate of second
neoplasias we found in GIST patients is obviously higher than expected. Several
reasons can be considered accountable for the development of multiple tumors in one
patient,  for  example,  similar  risk  factors,  environmental  factors,  or  genetic
predisposition, but also the higher likelihood of detection of another tumor within the
examinations  for  staging  or  follow-up.  In  cases  of  sporadic  GIST  there  are  no
definitely confirmed intrinsic risk factors or environmental factors. Genetic factors
play a role in syndromes such as neurofibromatosis type I or Carney triad, but these
patients were excluded in our study, and only patients with sporadic GIST were
included. The occurrence of GIST-specific mutations such as in the c-KIT or PDGFRα
gene that we found in the group of patients with GIST and second neoplasms were
similar to those reported for GIST in general before[5-7].
The localization of GIST-associated neoplasias with the highest frequency in the
gastrointestinal  tract,  the  urogenital,  and female  genital  tract  is  consistent  with
previously  reported findings[20,21].  In  addition  to  a  possible  common underlying
predisposition,  the  probability  of  detecting  even  small  GIST  during  staging
examinations for gastrointestinal tract tumors might be higher than in cases of, for
example, lung or head and neck tumors. This is might also be the explanation for the
high rate of 77% of GI-tract localization in synchronous second neoplasias.
The median age of the total study population compared to the group of patients
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Table 1  Case reports: Overview of tumor entities
Tumor entity Ref.
Gastrointestinal Tract
   Gastric adenocarcinoma
[29-55]
   Colorectal adenocarcinoma
[56-71]
   Gastric high grade IEN
[72]
   Esophagus SCC
[48,59,73]
   Esophagus Small Cell Carcinoma
[39]
   Gastro-esophageal junction adenocarcinoma
[74,75]
   Duodenum adenocarcinoma
[76]
   Papilla Vateri NET
[77]
   Gastric Lipoma
[78]
   Gastric NET
[79-82]
   Doudenum NET
[67]
   Ileum NET
[83]
   Gastric Schwannoma
[84]
   Colon NET
[85]
   Jejunal Sarcomatoid Carcinoma
[86]
   Pancreas adenosquamous carcinoma
[87,88]
   Pancreas adenocarcinoma
[89,90]
   Pancreas NET
[91-95]
   Hepatocellular carcinoma
[96-99]
   Cholangiocellular Carcinoma
[100,101]
   Perivascular Epitheloid Cell Tumor Liver
[102]
Urogenital Tract
   Renal Cell Carcinoma
[103,104]
   Renal Chromophobe Cell Carcinoma
[105]
   Prostate Adenocarcinoma
[40,69,82,106,107]
   Transitional Cell Carcnimona Bladder
[86]
Female Genitale Tract
   Ovarian Carcinoma
[108]
   Ovarian Serous Adenocarcinoma
[109,110]
   Uterus Leiomyoma
[91]
Breast
   Sarcoma
[111]
   Invasive Ductal Carcinoma
[55,61,63,92]
Blood/ Lymphatic
   Acute Myeloid Leukemia
[112-114]
   Acute Biphenotypic Leukemia
[100]
   Chronic Lymphoid Leukemia
[115]
   Low Grade B Cell Lymphoma Stomach
[116]
   Extranodal DLBCL
[117,118]
   Burkitt Lymphoma
[119]
   Mantle Cell Lymphoma Appendix
[120]
   MALT Lymphoma
[50,121]
   Multiple Myeloma
[122]
Head and Neck
   Oral Melanoma
[123]
   Papillary Thyroid Carcinoma
[124]
Lung
   Adenocarcinoma
[125-127]
   SCC
[107]
   NSCLC
[106]
Skin
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   Melanoma
[128,129]
   Squamous Cell Carcinoma
[130]
   Merkel Cell Carcinoma
[131]
Soft Tissue
   Myxofibrosarcoma
[82]
   Dermatofibrosarcoma
[132]
   Ewing Sarkoma
[133]
Others
   Adrenocortical Carcinoma
[134]
   Peritoneal Mesothelioma
[135]
   Mesenterial Fibromatosis
[136]
   Granular cell tumor
[55]
IEN: Intraepithelial neoplasia; SCC: Squamous-cell carcinoma; NET: Neuroendocrine tumor; DLBCL: Diffuse
large B cell lymphoma; MALT: Mucosa associated lymphatic tissue; NSCLC: Non-small cell lung cancer.
who developed a second tumor showed a difference of five years at the time-point of
GIST diagnosis, with the higher median age in the GIST with associated neoplasm
group.  A possible  explanation  for  this  finding  could  be  the  age-dependent  risk
increase for cancer in general[14]. Previously performed reviews on the topic of GIST
and associated neoplasms mostly concentrated on the occurrence rate and localization
of  the associated tumors and,  in  some cases,  on the outcome and follow-up[20-24].
Analysis of age or sex distribution have not been performed on larger numbers of
patients.  We  found  a  significantly  higher  number  of  male  patients  who  were
diagnosed with GIST and a second neoplasia than in the total population of GIST
patients. An equal sex distribution for GIST patients in general has been reported in
the literature before[1]. Regarding the overall incidence of cancer worldwide, the sex
distribution of patients diagnosed with cancer in 2018 is estimated at a male-to-female
ratio of 1.1:1 (9.5 million new cases in men and 8.6 million new cases in women).
Among gastrointestinal neoplasias, which were the most frequent GIST-associated
neoplasias in our review, there is a difference in the worldwide incidence between
men and women with a higher rate of gastrointestinal (GI) tumors diagnosed in men
in 2018 (2.7 million cases in men vs 1.4 million cases in women)[25]. Whether there is a
difference  of  distribution of  the  second neoplasias  between sexes  in  our  review
population remains unclear. In most analyzed studies, the reported data was not
sufficient to answer this question.
Several risk classification systems are used to assess the risk of disease progression
or recurrence of GIST[4,16]. Most of them use the size, localization, and mitotic rate of
GIST  and  are  therefore,  at  least  in  part,  comparable.  By  summarizing  the  risk
categories in two groups (very low and low vs intermediate and high), we could find
a significant difference between the GIST-only patients and those having GIST and
another neoplasia by using the chi-squared test. The patients with GIST-associated
neoplasias had lower risk scores, which might be due to a higher detection rate of
even small GISTs with low risk scores in the setting of another neoplastic disease.
Since the establishment of targeted therapies for GIST with imatinib or second-line
tyrosine kinase inhibitors, the prognosis even of advanced GIST has significantly
improved[26]. On the other side, there is growing interest in the question of elevated
risk of developing secondary neoplasia under the treatment with imatinib. Phan et al.
found a higher rate of secondary tumors among GIST patients in the imatinib era than
in the pre-imatinib era[27], although the most likely reason for this is the prolonged
survival even of patients with advanced GIST, as it has been described by different
authors[28]. Another point that relativizes the impact of imatinib on the development of
secondary tumors can be seen in our review: About 75% of associated neoplasias were
diagnosed either  before  GIST or  synchronously  with  GIST;  furthermore,  not  all
patients with a GIST diagnosis in advance were treated with imatinib.
In summary, in this,  to our knowledge first,  systematic review on the topic of
secondary neoplasia in patients with GIST, we confirm the previously described
elevated number of associated neoplasms and the most common localizations of this
neoplasms. We found a higher median age in the GIST with second neoplasia group
and significantly more male patients who developed associated tumors, whereas the
risk scores of GIST in this group were significantly lower. We conclude that even very
low-  and  low-grade  GISTs  should  be  a  reason  to  consider  frequent  controls  or
extended  staging  for  early  detection  of  second  neoplasias,  especially  in  the
gastrointestinal and urogenital tract. To understand whether there is an underlying
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Table 2  Retrospective and prospective studies used for this investigation
Patient characteristics Organ systems affected by associated NPL
Au-
thor Year
Date
of
diag-
nosis
N
Age average
(median) Sex m/f
Nu-
mber
(rate)
of
pati-
ents
with
ass.
NPL
GI-
tract
Liver/
gall
bla-
dder/
pan-
creas
Uro
geni-
tal
tract
Fem-
ale
geni-
tal
tract
Bre-
ast
Blo-
od/
lymp-
hatic
sys-
tem
Head
and
neck
Lung
Skin/
mela
noma
Soft OtherTotal
pop-
ula-
tion
Pat.
with
ass.
NPL
Total
pop-
ula-
tion
Pat.
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(6%)
101
(4%)
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(3%)
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genetic cause for the elevated rates of GIST-associated neoplasias, further studies will
be needed.
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Table 3  Age and sex distribution
Total study population GIST with associated neoplasia No. of patients available for calculation
Age (median) 63 68 4176/1139
Sex male: Female 1.1:1 1.4:1 10444/2080
GIST: Gastrointestinal stromal tumors.
Table 4  Characteristics of gastrointestinal stromal tumors and associated neoplasias
Parameter Quantification
No. of
patients
available
for
calculation
Designtion of associated NPL, n (%) Benigne 253 (11) 2248
Malignant 1995 (89)
Chronological presentation, n (%) Synchoronous 366 (50) 732
GIST first 179 (24)
Ass. NPL first 187 (26)
Histological subtypes of GIST, n (%) Spindle Total population 409 (78) 525; 185
GIST + ass. NPL 149 (80)
Epitheloid Total population 43 (8)
GIST + ass. NPL 11 (6)
Mixed Total population 73 (14)
GIST + ass. NPL 25 (14)
GIST: Gastrointestinal stromal tumors.
Table 5  Distribution of risk scores, n (%)
Risk score GIST without associated neoplasia GIST with associated neoplasia Total
Low and very low 123 (35) 230 (65) 353
Intermediate and high 373 (69) 165 (31) 538
Total 496 395 891
GIST: Gastrointestinal stromal tumors.
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Figure 2
Figure 2  Localization of gastrointestinal stromal tumor-associated neoplasias. GI: Gastrointestinal.
ARTICLE HIGHLIGHTS
Research background
In recent years, numerous case reports, mostly retrospective studies and a few reviews on the
topic of second neoplasias associated with gastrointestinal stromal tumors (GIST) have been
published. To our knowledge, however, this is the first systematic review of the existing data.
Research motivation
The aim of this review was to prepare a compilation, as complete as possible, of all reported
second tumor entities that have been described in association with GIST, and to systematically
analyze  the  published  studies  with  regard  to  frequency,  localization,  and  types  of  GIST-
associated neoplasms.
Research objectives
The main focus of this review was on frequency, localization, dependence of gender, age and
risk classification of GIST associated neoplasias. Summarizing the data of a large number of
patients could especially help in the daily clinical work with GIST patients.
Research methods
The  MEDLINE  and  EBSCO  databases  were  searched  for  a  combination  of  the  keywords
GIST/secondary, synchronous, coincident/tumor, neoplasm, and relevant publications were
selected by two independent  authors.  All  case  reports  were  summarized according to  the
reported tumor entity and included clinical studies were analyzed with regard to the previously
mentioned topics.
Research results
Of the initially found 3042 publications, 130 papers were selected; 22 of these were original
studies, and 108 were case reports. In the 22 selected studies, comprising a total number of 12050
patients, an overall rate of GIST-associated neoplasias of 20% could be calculated. Most second
neoplasias were found in the gastrointestinal tract (32%) and in the male and female urogenital
tract (30%). The male-to-female ratio revealed a predominance of male gender in cases with
associated neoplasia.  The  specific  risk  scores  of  GISTs  associated with  other  tumors  were
significantly lower than those of GIST without associated neoplasias. The question if there are
specific genetic mutations that occur with a higher frequency in GIST patients with second
tumors could not be answered and would be an interesting topic for future research.
Research conclusions
GISTs are associated with other neoplasias with a rate of 20% and occur most frequently in the
gastrointestinal and urogenital tract. This confirms previous findings on a larger number of
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patients. GIST associated neoplasias occur with a higher likelihood in older, male patients with
low grade GIST. 50% of GIST associated neoplasias are detected synchronously. Our findings
should be a reason to consider frequent controls or extended staging for early detection of
second neoplasias, especially in the gastrointestinal and urogenital tract.
Research perspectives
If there is a causal relation between GIST and second tumors remains unclear. As data on genetic
mutations of the GIST were reported very heterogeneously focusing on this topic could be an
interesting point for future research.
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